Article Sidebar

PDF
Date Published: 17/06/2022
Abstract Views: 240
Views PDF: 128
DOI: https://doi.org/10.51298/vmj.v513i2.2498
Issue
Vol. 513 No. 2 (2022)
Section
Các bài báo
How to Cite
Khắc Tấn, N. ., Thị Bình, L. ., Quốc Hoàn, P. ., & Phú Hùng, N. . (2022). EXPRESSION OF CANCER STEM CELL MARKERS (CD44, ALDH) AND HER2 IN GASTRIC ADENOCARCINOMA. Vietnam Medical Journal, 513(2). https://doi.org/10.51298/vmj.v513i2.2498

EXPRESSION OF CANCER STEM CELL MARKERS (CD44, ALDH) AND HER2 IN GASTRIC ADENOCARCINOMA

Nguyễn Khắc Tấn1,, Lưu Thị Bình2, Phan Quốc Hoàn3, Nguyễn Phú Hùng4
1 Polyclinics of Party organs in the Central Committee
2 Thai Nguyen University of Medicine and Pharmacy
3 108 Military Central Hospital
4 Thai Nguyen University of Sciences

Main Article Content

Abstract

Objective: To evaluate the expression of cancer stem cell immune markers (CD44, ALDH) and HER2 in gastric adenocarcinoma. Subject and Method: This was cross-sectional descriptive study; prospective design on 121 patients with confirmed diagnosis of gastric adenocarcinoma and surgical removal of the tumor at K Hospital. Evaluation of expression levels of markers HER2, CD44, ALDH in cancer samples and control samples. Result: The rate of gastric adenocarcinoma in men is higher than in women. The proportion of patients expressing HER2 at level 1+ (17.4%), level 2+ (14.9%) and 3+ (10.7%). The rate of HER2-positive patients was 25.6%. The percentage of patients with positive CD44 was 68.6%. Percentage of patients with positive ALDH was 61.2%. The expression rate of a single marker was 29.8%. Two markers simultaneously expressed the highest rate with 47.9%. The rate of simultaneous expression of both HER2, CD44 and ALDH was 9.9%. Conclusions: Immunomarker HER2 and cancer stem cells CD44, ALDH are expressed at different rates in gastric adenocarcinoma patients.

Article Details

Keywords

Immunomarker HER2, CD44, ALDH, immunohistochemistry, cancer stem cells

References

1. Matsusaka S., Nashimoto A., Nishikawa K., et al (2016) Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer 19(3): 839-851.
2. Eldeen Muhammad Alaa, Hashim Amal, Eid Refaat A., et al (2021) Molecular Targeting Of Breast Cancer Stem Cells: A Promising Strategy For Management And Eradication. European Journal of Molecular & Clinical Medicine 8(1): 1756-1768.
3. Takaishi S., Okumura T., Tu S., et al (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5): 1006-1020.
4. Nguyen P. H., Giraud J., Staedel C., et al (2016) All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. Oncogene 35(43): 5619-5628.
5. Smyth E. C., Verheij M., Allum W., et al (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5): v38-v49.
6. Abrahao-Machado L. F., Scapulatempo-Neto C. (2016) HER2 testing in gastric cancer: An update. World J Gastroenterol 22(19): 4619-4625.
7. Bao W., Fu H. J., Xie Q. S., et al (2011) HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 141(6): 2076-2087 e2076.
8. Huang J., Li H., Ren G. (2015) Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol 47(3): 840-848.